Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort.

[1]  P. Ponikowski,et al.  How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2020, European journal of heart failure.

[2]  Zhuyin Li,et al.  Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. , 2020, Journal of the American College of Cardiology.

[3]  A. Leite-Moreira,et al.  Relaxin and the Cardiovascular System: From Basic Science to Clinical Practice. , 2020, Current molecular medicine.

[4]  T. Dschietzig.  Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials , 2019, Molecular and Cellular Endocrinology.

[5]  A. Mebazaa,et al.  The relationship of circulating relaxin‐2 concentrations with short‐term prognosis in patients with acute heart failure: the RELAHF study , 2017, European journal of heart failure.

[6]  A. Leite-Moreira,et al.  Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload , 2017, European journal of heart failure.

[7]  R. Wachter,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. , 2016, European heart journal.

[8]  J. Sánchez-Más,et al.  Relaxin Concentrations in Acute Heart Failure Patients: Kinetics and Clinical Determinants. , 2016, Revista espanola de cardiologia.

[9]  F. Rutten,et al.  Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review , 2016, European journal of heart failure.

[10]  Yuanzhao Chen,et al.  H2 relaxin expression and its effect on clinical outcomes in patients with chronic heart failure. , 2015, International journal of clinical and experimental medicine.

[11]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[12]  J. McMurray,et al.  N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure , 2003, Heart.

[13]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .

[14]  Human Experimentation: Code of Ethics of the World Medical Association (Declaration of Helsinki). , 1964, Canadian Medical Association journal.